Zaleplon as safe hypnotic Review article
Article Sidebar
Main Article Content
Abstract
Zaleplon is non-benzodiazepine, pyrazolopyrimidine hypnotic drug indicated for the short-term management of insomnia. Zaleplon shortens seep latency. It has half-life of about an hour, and thanks to this unique characteristic it can be administered in the middle-of-the-night mode. Efficacy studies show that zaleplon is a suitable hypnotic for sleep initiation and maybe less effective in sleep maintenance. The use of zaleplon is relatively safe. The biggest advantage of zaleplon is that current evidence suggests it does not produce residual next-day side effects. Four hours after intake of zaleplon no effect on cognitive, memory, psychomotor performance and the ability to drive a car have been reported. That’s why it seems to be safe in elderly group of patients and those who are likely to drive a car.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. American Academy of Sleep Medicine. The International Classification of Sleep Disorders, Diagnostic and Coding Manual. Wyd. II. American Academy of Sleep Medicine; Westchester, Illinois, 2005.
3. Szelenberger W. Zasady leczenia bezsenności. Standardy Medyczne w Praktyce, Warszawa 2012.
4. Ministerstwo Zdrowia Departament Polityki Lekowej i Farmacji. Zaleplon. Charakterystyka produktu leczniczego. Warszawa 2008.
5. Wciórka J, Pużyński S, Rybakowski J. Psychiatria. Tom III. Elsevier Urban & Partner; Wrocław 2012: 152-155.
6. Szelenberger W. Bezsenność. Wydanie II. Via Medica; Gdańsk 2007: 54-55.
7. Monti JM, Pandi-Perumal SR, Möhler H. GABA and Sleep: Molecular, Functional and Clinical Aspects. Springer; Basel 2010: 468-474.
8. Wciórka J, Pużyński S, Rybakowski J. Psychiatria. Tom III. Elsevier Urban & Partner; Wrocław 2012: 219.
9. Hedner J, Yaeche R, Emilien G, Farr I, Salinas E. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatry 2000; 15 (8): 704-712.
10. Walsh JK, Fry J, Richardson GS, Scharf MB, Vogel GW. Short term efficacy of zaleplon in older patients with chronic insomnia. Clin Drug Invest 2000; 20(3): 143-149.
11. Hesse LM, von Moltke LL, Greenblatt DJ. Clinically important drug interaction with zopiclone, zolpidem and zaleplon. CNS Drugs 2003; 17(7): 513-532.
12. Sanchez Garcia P, Carcas A, Zapater P, Rosendo J, Paty I, Leister CA. Absence of an interaction between ibuprofen and zaleplon. Am J Health Syst Pharm 2000; 57(12): 1137-1141.
13. Sanchez Garcia P, Paty I, Leister CA, Guerra P, Frias J, Garcia Perez LE, Darwish M. Effect of zaleplon on digoxin pharmacokinetics and pharmacodynamics. Am J Health Syst Pharm 2000; 57(24): 2267-2270.
14. Andersen AB, Frydenberg M. Long-term use of zopiclone, zolpidem and zaleplon among Danish elderly and the association with sociodemographic factors and use of other drugs. Pharmacoepidemiol Drug Saf 2011; 20(4): 378-385.
15. Ebbens MM, Verster JC. Clinical evaluation of zaleplon in treatment of insomnia. Nature and Science of Sleep 2010; 2: 115-126.